- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:00 | IDL Diagnostics AB: IDL Diagnostics (publ) Interim Report January 1 - March 31, 2026 | 3 | GlobeNewswire (Europe) | A word från the CEO "IDL Diagnostics has started 2026 with the strongest quarter in the company's history, and the clear growth trend that we began to see toward the end of last year has continued.... ► Artikel lesen | |
| 05.03. | IDL Diagnostics AB: Anders Hultman will be stepping down as CEO of IDL Diagnostics | 135 | GlobeNewswire (Europe) | The Board of Directors of IDL Diagnostics AB (publ) ("IDL Diagnostics") and CEO Anders Hultman have today agreed that Anders will be leaving his role as CEO of IDL Diagnostics.
"Anders Hultman has,... ► Artikel lesen | |
| 26.02. | IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to December 31st, 2025 | 119 | GlobeNewswire (Europe) | A word from the CEO"IDL Diagnostics ends 2025 with a strong quarter, achieving the highest revenue for a single quarter in the company's history. During the year, the number of tests sold in our urology... ► Artikel lesen | |
| 12.11.25 | IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to September 30th, 2025 | 256 | GlobeNewswire (Europe) | A word from the CEO"We are pleased to report continued progress for our UBC bladder cancer test during the past quarter. UBC tests continue to show steady growth, reflecting the strength of our products... ► Artikel lesen | |
| 10.11.25 | IDL Diagnostics AB: First commercial order from Japanese partner secured for the Chinese market | 192 | GlobeNewswire (Europe) | IDL Diagnostics has secured its first commercial order for TPS CLIA from its Japanese partner, a leading global Japanese IVD company, for deployment within the Chinese market.
"I am happy to announce... ► Artikel lesen | |
| 29.09.25 | IDL Diagnostics AB: IDL Diagnostics secures patent approval in Hong Kong for the use of TK1 protein in respiratory infections | 291 | GlobeNewswire (Europe) | IDL Diagnosticsl AB (publ) is pleased to announce that its patent application (HK40055647) for the novel use of thymidine kinase 1 (TK1) protein in detecting and categorizing respiratory infections... ► Artikel lesen | |
| 21.08.25 | IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to June 30th, 2025 | 233 | GlobeNewswire (Europe) | A word from the CEO"In the second quarter, we have focused on creating a stable foundation to broaden and develop our sales, both in existing and upcoming new markets. A crucial factor for success is... ► Artikel lesen | |
| IDL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 12.08.25 | IDL Diagnostics AB: New Study Highlights Potential of IDL diagnostics biomarkers TK1 and TPS in Guiding Therapy for Advanced Prostate Cancer | 475 | GlobeNewswire (Europe) | A new scientific study that has been accepted for publication in Urologic Oncology: Seminars and Original Investigations demonstrates a useful clinical application of two IDL Diagnostics blood biomarkers:... ► Artikel lesen | |
| 27.05.25 | IDL Diagnostics AB: AroCell changes name to IDL Diagnostics AB | 402 | GlobeNewswire (Europe) | AroCell AB (publ) today announces that the company will change its name to IDL Diagnostics AB in accordance with a resolution made at AroCell's Annual General Meeting on 15 May 2025. On 27 May, trading... ► Artikel lesen | |
| 26.05.25 | Change of company name and ticker for AroCell AB | 455 | GlobeNewswire | As from May 27, 2025, AroCell AB will change company name to IDL Diagnostics AB (publ).
Old company name: AroCell AB
New company name: IDL Diagnostics AB (publ)
Old ticker: AROC
New... ► Artikel lesen | |
| 15.05.25 | AroCell AB: Report from AroCell's Annual General Meeting 2025 | 408 | GlobeNewswire (Europe) | (Available in Swedish only)
Nedan redovisas de väsentliga beslut som fattades vid AroCells årsstämma tidigare idag den 15 maj 2025. Stämman hölls i AroCells lokaler i Stockholm samt genom poströstning.... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 115,02 | +0,05 % | Gilead: Erwartungen übertroffen - darum fällt die Aktie trotzdem | Die Biotech-Gesellschaft Gilead Sciences hat am Donnerstagabend nach US-Börsenschluss die Zahlen für das erste Quartal des neuen Geschäftsjahres veröffentlicht. Trotz besser als erwarteter Vorgaben... ► Artikel lesen | |
| TILRAY BRANDS | 4,615 | 0,00 % | Tilray Brands Inc (2): Tilray Brands' Blue Point rolls out Magic Hour IPA | ||
| VERTEX PHARMACEUTICALS | 380,65 | -0,33 % | Vertex Pharmaceuticals Incorporated: Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany | -The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Resignation of Director | Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the cannabis... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 11,035 | -2,60 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights | In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading... ► Artikel lesen | |
| GSK | 21,790 | 0,00 % | GSK findet für neues Hepatitis-Medikament Vertriebspartner in China | DJ GSK findet für neues Hepatitis-Medikament Vertriebspartner in China
Von Adria Calatayud
DOW JONES--GSK kooperiert mit Sino Biopharmaceutical, um die Markteinführung für sein Hepatitis-B-Medikament... ► Artikel lesen | |
| MERCK KGAA | 122,25 | +8,19 % | Merck erhöht Prognose nach solidem Jahresauftakt | DJ Merck erhöht Prognose nach solidem Jahresauftakt
DOW JONES--Der Pharma- und Technologiekonzern Merck hat seine Jahresprognose nach einem soliden ersten Quartal angehoben. Der Umsatz und das... ► Artikel lesen | |
| BAYER | 38,480 | +0,10 % | Bayer: Anleger feiern überraschende Ergebnisdynamik | Bayer überrascht mit einem kräftigen Gewinnsprung und hebt die Prognose für 2026 an. Vor allem das Agrargeschäft glänzt, während das Pharma-Segment weniger stark einbricht als befürchtet. So prognostiziert... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,170 | +0,24 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 29,730 | +0,07 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| NOVO NORDISK | 40,250 | +1,50 % | Starke Geschäfte mit der Wegovy-Pille bescheren Novo Nordisk erfreuliche Zahlen und eine klare Erholung an der Börse | Novo Nordisk blickt an der Börse auf eine schmerzhafte Talfahrt zurück. Bedingt durch den harten Konkurrenzkampf in den USA konnten die Absatzmengen in der jüngeren Vergangenheit nicht immer überzeugen... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 15,950 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,490 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| ZOETIS | 66,20 | +1,01 % | Zoetis Inc. Q1 Sales Increase | WASHINGTON (dpa-AFX) - Zoetis Inc. (ZTS) revealed a profit for first quarter of $601 millionThe company's bottom line came in at $601 million, or $1.42 per share. This compares with $602 million... ► Artikel lesen | |
| SCHOTT PHARMA | 15,440 | -1,66 % | EQS-News: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma mit robustem erstem Halbjahr und starkem Cashflow | EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
SCHOTT Pharma mit robustem erstem Halbjahr und starkem Cashflow
13.05.2026 /... ► Artikel lesen |
IDL DIAGNOSTICS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (-1,06 %) liegt der Kurs bei 0,019 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IDL DIAGNOSTICS AB finden Sie auf Wallstreet Online.